- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Immune monitoring and treatment in immune-mediated inflammatory diseases ; volume:13 ; number:1 ; day:7 ; month:6 ; year:2022 ; pages:1 ; date:12.2022
Nature Communications ; 13, Heft 1 (7.6.2022), 1, 12.2022
- Urheber
-
Wijk, Femke van
Bruin, Marjolein de
Leavis, Helen
Nierkens, Stefan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-022-30891-7
- URN
-
urn:nbn:de:101:1-2022080710375959171447
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wijk, Femke van
- Bruin, Marjolein de
- Leavis, Helen
- Nierkens, Stefan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cancer risk in immune-mediated inflammatory diseases (IMID)
Urine metabolome profiling of immune-mediated inflammatory diseases
IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
CXCL13: a common target for immune-mediated inflammatory diseases
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease
Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases
Recent advances of exosomes in immune-mediated eye diseases
Cancer risk in immune-mediated inflammatory diseases (IMID)
Urine metabolome profiling of immune-mediated inflammatory diseases
IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
CXCL13: a common target for immune-mediated inflammatory diseases
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease
Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases
Recent advances of exosomes in immune-mediated eye diseases
Cancer risk in immune-mediated inflammatory diseases (IMID)
Urine metabolome profiling of immune-mediated inflammatory diseases
IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
CXCL13: a common target for immune-mediated inflammatory diseases
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease
Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases